Join Growin Stock Community!

Tempest therapeutics, inc.TPST.US Overview

US StockHealthcare
(No presentation for TPST)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

TPST AI Insights

TPST Overall Performance

TPST AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

TPST Recent Performance

-1.10%

Tempest therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

TPST PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

TPST Key Information

TPST Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

TPST Profile

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.

Price of TPST

TPST FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

TPST Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-7.32
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
1.74
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-7.32
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
1.74
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is TPST's latest earnings report released?

    The most recent financial report for Tempest therapeutics, inc. (TPST) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating TPST's short-term business performance and financial health. For the latest updates on TPST's earnings releases, visit this page regularly.

  • How much debt does TPST have?

    As of the end of the reporting period, Tempest therapeutics, inc. (TPST) had total debt of 8.41M, with a debt ratio of 0.49. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does TPST have?

    At the end of the period, Tempest therapeutics, inc. (TPST) held Total Cash and Cash Equivalents of 7.51M, accounting for 0.44 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is TPST's EPS continuing to grow?

    According to the past four quarterly reports, Tempest therapeutics, inc. (TPST)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.79. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of TPST?

    Tempest therapeutics, inc. (TPST)'s Free Cash Flow (FCF) for the period is -6.78M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 33.52% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.